Shares of Solid Biosciences crater as FDA halts Duchenne gene therapy trial
Less than two months after pulling off one of the biggest initial public offerings for a local biotech in recent years, Cambridge-based Solid Biosciences said that the FDA had halted a trial of its gene therapy treatment for Duchenne muscular dystrophy, sending shares of the company into a tailspin.
Solid (Nasdaq: SLDB) said Wednesday that the FDA had stopped an early-stage study of the drug after one patient was hospitalized due to reduced platelet and red blood cell count. The company added that…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Max Stendahl Source Type: news
More News: Biotechnology | Gene Therapy | Genetics | Health Management | Muscular Dystrophy | Reflex Sympathetic Dystrophy | Study